Assessing long-term use of Risankizumab for Psoriatic Arthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the long-term effectiveness and persistence of treatment with Risankizumab in adults diagnosed with psoriatic arthritis, compared to other advanced therapeutic options. It will involve approximately 900 to 1200 participants across 15 countries, focusing on those who have had an inadequate response to at least one disease-modifying antirheumatic drug. The study aims to gather real-world data on the management of psoriatic arthritis in clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease.
* Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator.

Exclusion Criteria:

\- Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).

Where it's running

• Cer Instituto Médico /ID# 274445
  Quilmes, Buenos Aires, Argentina Recruiting
• Instituto Medico de Alta Complejidad San Isidro S.A. /ID# 274417
  San Isidro, Buenos Aires, Argentina Recruiting
• Instituto Médico Río Cuarto /ID# 274421
  Río Cuarto, Córdoba Province, Argentina Recruiting
• Landesklinikum Stockerau /ID# 275618
  Stockerau, Lower Austria, Austria Recruiting
• Rheuma-Zentrum Wien-Oberlaa GmbH /ID# 275617
  Vienna, State of Vienna, Austria Recruiting
• Medizinische Universitaet Graz /ID# 273765
  Graz, Styria, Austria Recruiting

+82 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Shari Chapman
• Email: shari.chapman@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Risankizumab for Refractory Perianal Fistulizing Crohn's Disease

  This study tests whether risankizumab can help people with Crohn’s disease who have draining perianal fistulas not responding to other treatments.

  Recruiting Phase 4 Hyogo Medical University · Nishinomiya and 3 other locations · NCT07872449

• HLA B Leader in Psoriatic Arthritis

  This study tests whether the HLA B leader gene is more common in people with psoriatic arthritis than in healthy individuals.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT07718815

• TaVNS for Psoriatic Arthritis in Adults

  This study tests whether non-invasive taVNS can help reduce disease activity and improve pain and quality of life in adults with psoriatic arthritis.

  Recruiting Marmara University · Istanbul · NCT07653009

• Guselkumab versus risankizumab for moderate-to-severe Crohn's disease

  This comparison tests whether guselkumab or risankizumab works better to reduce intestinal inflammation in people with moderately to severely active Crohn's disease.

  Recruiting at 162 sites Phase 3 Janssen Research & Development, LLC · Dothan, Alabama and 163 other locations · NCT07499232

• How risankizumab moves through the body after IV vs SC dosing in healthy adults

  This study tests how risankizumab behaves in the body after intravenous and subcutaneous doses in healthy adult volunteers.

  Recruiting at 2 sites Phase 1 AbbVie · Anaheim, California and 1 other locations · NCT07466550

• TQH3906 capsules for active psoriatic arthritis in adults

  This trial tests whether TQH3906 capsules help people with active psoriatic arthritis more than a placebo over 12 weeks.

  Recruiting at 36 sites Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Bozhou, Anhui and 43 other locations · NCT07406035

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.